Breath Diagnostics

The future of patient health diagnostics

Breath Diagnostics

nGageIT patent pending Nanosmart™ technology is being used to develop portable accurate mobile handheld breath diagnostic technology that can be easily deployed in health systems at an affordable cost.
We are also developing the worlds largest data library of cancer bio-markers in the breath, with the ability to detect numerous forms of cancers and other illnesses. The metabolism of people with lung cancer, pancreatic cancer and breast cancer is different to that of healthy people and this is reflected in the chemical signature of their breath.

Breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside. 
People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.

More than 80% of lung cancer patients will survive for at least a year if diagnosed at the earliest stage compared to around 15% for people diagnosed with the most advanced stage of disease.

Survival rates comparing stage 1 and stage 4 lung cancer

Stage 1 The overall 5-year survival rate for stage 1A lung cancer is 49 percent and for 1B is 45 percent
Stage 4 Less than 10% survival rate

Early cancer detection saves lives.

Our breath diagnostic technology can significantly increase early-stage cancer detection rates among patient populations, resulting in more early stage diagnoses and much greater life expectancy for patient populations.

Areas of Development

Pancreatic Cancer

Pancreatic cancer carries a very poor prognosis as most patients are diagnosed symptomatically at an advanced stage. nGageIT is developing breath diagnostic technology that is being designed to help detect pancreatic cancer earlier, when life saving treatments with higher outcomes may be possible.

Pancreatic cancer is the fourth largest cause of cancer related deaths worldwide. Most patients are diagnosed at a time when the cancer has spread and has become a more aggressive form, and so chances of survival are slim. Scientists have recognized a lack of effective and objective diagnostic methods for pancreatic cancer and continue to look for ways to diagnose people earlier. Currently, only 15-20 percent of patients have potentially curable diseases at the time of diagnosis.

Colon Cancer

nGageIT is developing easy to use handheld, mobile breath detection nano-technology to analyze for colorectal cancer at an early stage, in the hope of improving survival rates from the disease, which is the second most common cancer killer worldwide with 215,000 deaths every year.

Current faecal screening tests have a low compliance rate which, combined with relatively low test sensitivity particularly in early disease stages, results in a high proportion of patients being diagnosed with late stage disease, leading to poor patient outcomes.

Breast Cancer

Currently, clinicians must review 300 screening mammograms to discover one woman with breast cancer. nGageIT is developing a mobile breath sensor platform that runs from a device the size of smartphone that might improve these very low screening rates.

Normal human breath contains more than 1000 different volatile organic compounds (VOCs), and some have been identified as candidate biomarkers of breast cancer. nGageIT’s NanoSensor enabled mobile smart phone based sensor is being developed to select for these specific cancer markers .

Lung Cancer

nGageIT’s NanoSensor can also be used in the future to correlate medication adherence to oral oncology medications with biomarker performance in real time. This powerful tool will allow clinicians to truly precisely tailor therapy and dose to an individual patients physiological nuances.